Skip to main content
. 2017 Mar 15;7:44275. doi: 10.1038/srep44275

Figure 2. Expression of TBL1XR1 in stage IV CRCLM patients and its clinical significance.

Figure 2

(A–H) Representative IHC results towards TBL1XR1 in TNM stage IV primary CRC tissues and liver metastases, showing different immunoreactivity score (IRS) among patients. (A,B) Low TBL1XR1 expression images in primary tumor tissues. (C,D) High TBL1XR1 expression in primary tumor tissues. (E,F) Low TBL1XR1 expression in liver metastases. (G,H) High TBL1XR1 expression in liver metastases. High expression of TBL1XR1 in primary tumor tissues (I) or liver metastases (J) were both correlated with poor disease-free survival (P = 0.014 and P = 0.041, respectively). Magnification: 200X. *Indicated statistical significance.